Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Personalis Awarded New Contract with the US Department of Veterans Affairs to Provide Clinical Cancer Genomic Testing and Analysis for the Precision Oncology Program

Personalis,Inc.
Posted on: 30 Nov 17

Personalis, Inc., a provider of advanced genomic sequencing and analytics for cancer and immuno-oncology, today announced that the company has been awarded a new contract by the US Department of Veterans Affairs (VA) to provide clinical cancer genomic testing and analysis for the VA’s Precision Oncology Program (POP). Personalis will perform these services through its ACE CancerPlus™ Test, which combines DNA and RNA analysis to provide physicians with clinical interpretation of genetic alterations of medical importance in 181 genes.

The ACE CancerPlus Test uses Personalis’ patented Accuracy and Content Enhanced (ACE) Technology platform to provide high accuracy, clinical-grade next-generation sequencing and analysis, to identify base substitutions, insertions/deletions (indels), copy number alterations (CNAs) and gene fusions. This provides comprehensive and detailed genomic profiling of solid tumors for the identification of potential treatment and clinical trial options for VA Healthcare System patients.

This is Personalis’ 6th contract for sequencing and analysis from the US Department of Veterans Affairs (VA), and the 2nd for clinical analysis of patient samples. Personalis was also recently awarded a new contract for the VA’s Million Veteran Program, launched in 2011, a landmark research effort aimed at better understanding how genetic variations affect health – building one of the world’s largest medical databases by combining genetic analysis with health, lifestyle, military exposure information and medical records from one million veteran volunteers.

"It is a great privilege working with the VA to ensure that our veterans have access to the latest cancer therapies based on their tumor's unique genetic makeup. We look forward to expanding the test to more VA sites, as well as to supporting new indications,” said Dr. Richard Chen, MD, CSO at Personalis.

John West, President and CEO of Personalis said: “We are extremely pleased to continue our relationship with the VA and support the VA’s leadership using genomics to improve veterans’ medical care. Through this VA partnership Personalis has further optimized its platform for difficult-to-sequence FFPE samples, which has resulted in improved sequencing performance for VA customers as well as for customers of its ACE ImmunoID platform.”

About Personalis, Inc.

Personalis, Inc. (www.personalis.com) is a leading precision medicine company focused on advanced NGS-based services for immuno-oncology and cancer for clinical trials and translational research. Personalis also provides DNA and RNA sequencing and data analysis of human genomes.

The Personalis ACE Exome and Transcriptome technology is designed to obtain the most comprehensive and accurate tumor molecular profile and each tumor’s unique immune microenvironment for immuno-oncology applications. The company’s clinical laboratory is GCP compliant, CLIA licensed and CAP accredited. Personalis is differentiated by advanced sequencing assays, algorithms and content for neoantigen characterization, customer regulatory support, and more. Visit our website at www.personalis.com and follow @PersonalisInc.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171130005319/en/

Business Wire
www.businesswire.com

Last updated on: 30/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.